파브리병 치료 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 약제별, 치료별, 투여 경로별, 유통 채널별, 지역별 부문, 경쟁(2020-2030년)
Fabry Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drugs, By Treatment, By Route of Administration, By Distribution Channel, By Region & Competition, 2020-2030F
세계 파브리병 치료 시장은 2024년 18억 6,000만 달러로 평가되었고, 2030년까지 6.30%의 연평균 복합 성장률(CAGR)을 나타내며 예측 기간 동안 괄목할 만한 성장을 이룰 것으로 예상됩니다.
패브리병은 앤더슨 패브리병으로도 알려져 있으며, 리소좀 저장 장애로 알려진 질환군에 속하는 희귀한 유전성 질환입니다. 이 질환은 α-갈락토시다아제 A(α-Gal A)라는 효소를 암호화하는 GLA 유전자의 돌연변이로 인해 발생합니다. 이 효소가 결핍되면 글로보트리아오실세라미드(Gb3 또는 GL-3)로 알려진 특정 유형의 지방 물질이 전신 세포에 축적됩니다. 이 Gb3의 축적은 주로 혈관, 신장, 심장, 신경계 세포에 영향을 미쳐 다양한 증상과 합병증을 유발합니다. 패브리병의 증상은 대부분 소아기 또는 청소년기에 나타나지만, 증상의 발현 연령과 중증도는 환자에 따라 매우 다양합니다. 파브리병의 특징적인 증상 중 하나는 신경병증성 통증으로 심각하고 만성화될 수 있습니다. 이 통증은 보통 손이나 발과 같은 사지에 발생하며, 종종 작열감이나 통증으로 표현됩니다. 예를 들어, 미국 파브리병 재단(NFDF)에 따르면 미국에서는 매년 4월을 파브리병 인식의 달로 지정하고 있습니다. 인식 제고 프로그램은 일반 시민, 환자, 간병인, 의료 전문가들의 교육에 초점을 맞추었습니다. 이러한 이니셔티브는 파브리병에 대한 이해, 진단 및 관리를 개선하는 것을 목표로 하며, 궁극적으로 연구 기간 동안 시장 성장에 기여할 것입니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
18억 6,000만 달러 |
| 시장 규모 : 2030년 |
26억 6,000만 달러 |
| CAGR : 2025-2030년 |
6.30% |
| 급성장 부문 |
온라인 약국 |
| 최대 시장 |
북미 |
시장 성장 촉진요인
진단의 발전
주요 시장 이슈
제한된 환자 수
주요 시장 동향
바이오마커 개발
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 파브리병 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 약제별(Agalsidase Beta, Migalastat, 기타)
- 치료별(효소 대체 요법(ERT), 샤프론 치료, 기질 감소 요법(SRT), 기타)
- 투여 경로별(경구, 비경구, 기타)
- 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 아시아태평양의 파브리병 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
제7장 유럽의 파브리병 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 유럽 : 국가별 분석
제8장 북미의 파브리병 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 북미 : 국가별 분석
제9장 남미의 파브리병 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 파브리병 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 파브리병 치료 시장 : SWOT 분석
제14장 Porter의 Five Forces 분석
- 업계내 경쟁
- 신규 참여 가능성
- 공급업체의 힘
- 고객의 힘
- 대체품의 위협
제15장 PESTEL 분석
제16장 경쟁 구도
- Sanofi(Genzyme Corporation)
- Takeda Pharmaceutical Company Limited
- Amicus Therapeutics, Inc
- JCR Pharmaceuticals Co., Ltd.
- Protalix BioTherapeutics Inc.
- Chiesi Farmaceutici S.p.A.
- Freeline Therapeutics Holdings PLC
- Yuhan Corporation
- M6P Therapeutics
- ISU Abxis Co Ltd
제17장 전략적 제안
제18장 리서치사에 대해 & 면책사항
LSH
Global Fabry Disease Treatment Market was valued at USD 1.86 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 6.30% through 2030. Fabry disease, also known as Anderson-Fabry disease, is a rare and inherited genetic disorder that belongs to a group of conditions known as lysosomal storage disorders. This disease is caused by mutations in the GLA gene, which encodes an enzyme called alpha-galactosidase A (alpha-Gal A). The deficiency of this enzyme results in the accumulation of a specific type of fatty substance, known as globotriaosylceramide (Gb3 or GL-3), within cells throughout the body. This buildup of Gb3 primarily affects the cells of blood vessels, kidneys, heart, and nervous system, leading to a wide range of symptoms and complications. Symptoms of Fabry disease often appear in childhood or adolescence, although the age of symptom onset and their severity can vary widely among affected individuals. One of the hallmark symptoms of Fabry disease is neuropathic pain, which can be severe and chronic. This pain typically affects the extremities, such as the hands and feet, and is often described as burning or tingling. For instance, according to the National Fabry Disease Foundation (NFDF) designates April as Fabry Disease Awareness Month each year in the United States. Awareness programs focus on educating the public, patients, caregivers, and healthcare professionals. These initiatives aim to improve the understanding, diagnosis, and management of Fabry disease, ultimately contributing to market growth throughout the study period.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 1.86 Billion |
| Market Size 2030 | USD 2.66 Billion |
| CAGR 2025-2030 | 6.30% |
| Fastest Growing Segment | Online Pharmacies |
| Largest Market | North America |
Key Market Drivers
Advancements in Diagnosis
Genetic testing has become a cornerstone in the diagnosis of Fabry disease. Advances in genetic sequencing technology have made it more accessible and cost-effective to identify specific mutations in the GLA gene, which is responsible for the disease. Genetic testing can confirm the presence of Fabry disease and provide information about the specific genetic mutations involved. In some regions, newborn screening programs have been implemented to identify Fabry disease in infants shortly after birth. This early detection allows for prompt intervention and treatment, potentially preventing or delaying the onset of symptoms and organ damage. Researchers have been investigating biomarkers associated with Fabry disease. Biomarkers are measurable substances in the body that can indicate the presence of a disease or its progression. Biomarker research can aid in early diagnosis and monitoring the effectiveness of treatment. Clinical diagnostic criteria for Fabry disease have been refined and standardized. Healthcare professionals now have clearer guidelines and criteria to assist in diagnosing disease based on clinical symptoms and genetic testing results. For instance, in December 2022, Bio Sidus SA sponsored a clinical trial to assess the efficacy and safety of AGA BETA BS in FD patients previously stabilized with Fabrazyme. Also, Fabry disease pipeline products continue to drive market growth. For example, in August 2021, the European Commission approved Amicus Therapeutics' Galafold for long-term treatment of Fabry disease in patients aged 12 and above with an amenable mutation.
Key Market Challenges
Limited Patient Population
The small patient population with Fabry disease results in a limited market size for pharmaceutical companies. This can make it less economically attractive for these companies to invest in research and development of treatments for disease. Developing and gaining regulatory approval for new treatments, including clinical trials and research, is costly. In the case of rare diseases like Fabry disease, the small number of potential patients can make it challenging to recoup these expenses. Due to the small market size, the revenue potential for treatments for Fabry disease may be limited compared to drugs for more common conditions. This can affect the profitability of drug development efforts. Limited patient populations can result in challenges related to patient access to treatments and affordability. Even if effective treatments exist, they may not be accessible to all patients due to cost or availability. The rarity of Fabry disease can lead to delayed diagnosis or misdiagnosis, as healthcare providers may not be familiar with the condition. This can result in patients not receiving appropriate treatment until the disease has progressed. Limited patient populations can also result in a scarcity of clinical data on the disease and its treatment. This can make it challenging for healthcare providers to make informed treatment decisions. Recognizing the challenges posed by rare diseases, some regulatory agencies provide incentives for orphan drug development. These incentives can include extended market exclusivity and reduced regulatory fees.
Key Market Trends
Biomarker Development
Biomarkers can aid in the early diagnosis of Fabry disease, allowing for timely intervention and treatment initiation. Early diagnosis is essential for preventing or delaying the onset of symptoms and organ damage. Biomarkers can be used to monitor disease progression and assess the effectiveness of treatment over time. This enables healthcare providers to tailor treatment plans to individual patients' needs. Certain biomarkers may be associated with the severity of Fabry disease. Identifying these biomarkers can help predict disease outcomes and guide treatment decisions. Biomarkers can help determine how well a patient is responding to treatment. If treatment is effective, biomarkers may show improvements in disease-related indicators. Biomarkers can serve as valuable endpoints in clinical trials of new Fabry disease treatments. They provide objective measures of treatment efficacy and safety. The development of biomarkers supports the concept of personalized medicine, where treatments are tailored to individual patients based on their biomarker profiles. This approach can optimize treatment outcomes. Biomarkers provide insights into the underlying molecular and genetic mechanisms of Fabry disease. This knowledge can inform drug development efforts, leading to more targeted and effective therapies. Biomarkers can be used to stratify Fabry disease patients into different subgroups based on disease characteristics. This stratification can guide treatment decisions and improve patient outcomes. Biomarkers can help reduce diagnostic delays by providing objective evidence of Fabry disease. This is particularly important because Fabry disease is often underdiagnosed or misdiagnosed.
Key Market Players
- Sanofi (Genzyme Corporation)
- Takeda Pharmaceutical Company Limited
- Amicus Therapeutics, Inc
- ISU ABXIS Co Ltd.
- JCR Pharmaceuticals Co., Ltd.
- Protalix BioTherapeutics Inc.
- Chiesi Farmaceutici S.p.A.
- Freeline Therapeutics Holdings PLC
- Yuhan Corporation
- M6P Therapeutics Inc.
Report Scope:
In this report, the Global Fabry Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Fabry Disease Treatment Market, By Drugs:
- Agalsidase Beta
- Migalastat
- others
Fabry Disease Treatment Market, By Treatment:
- Enzyme Replacement Therapy (ERT)
- Chaperone Treatment
- Substrate Reduction Therapy (SRT)
- Others
Fabry Disease Treatment Market, By Route of Administration:
Fabry Disease Treatment Market, By Distribution Channel:
- Hospital pharmacies
- Retail pharmacies
- Online Pharmacies
Fabry Disease Treatment Market, By region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Fabry Disease Treatment Market.
Available Customizations:
Global Fabry Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Fabry Disease Treatment Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Drugs (Agalsidase Beta, Migalastat, others)
- 5.2.2. By Treatment (Enzyme Replacement Therapy (ERT), Chaperone Treatment, Substrate Reduction Therapy (SRT), others)
- 5.2.3. By Route of Administration (Oral, Parenteral, others)
- 5.2.4. By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online Pharmacies)
- 5.2.5. By Region
- 5.2.6. By Company (2024)
- 5.3. Market Map
6. Asia Pacific Fabry Disease Treatment Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Drugs
- 6.2.2. By Treatment
- 6.2.3. By Route of Administration
- 6.2.4. By Distribution Channel
- 6.2.5. By Country
- 6.3. Asia Pacific: Country Analysis
- 6.3.1. China Fabry Disease Treatment Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Drugs
- 6.3.1.2.2. By Treatment
- 6.3.1.2.3. By Route of Administration
- 6.3.1.2.4. By Distribution Channel
- 6.3.2. India Fabry Disease Treatment Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Drugs
- 6.3.2.2.2. By Treatment
- 6.3.2.2.3. By Route of Administration
- 6.3.2.2.4. By Distribution Channel
- 6.3.3. Australia Fabry Disease Treatment Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Drugs
- 6.3.3.2.2. By Treatment
- 6.3.3.2.3. By Route of Administration
- 6.3.3.2.4. By Distribution Channel
- 6.3.4. Japan Fabry Disease Treatment Market Outlook
- 6.3.4.1. Market Size & Forecast
- 6.3.4.2. Market Share & Forecast
- 6.3.4.2.1. By Drugs
- 6.3.4.2.2. By Treatment
- 6.3.4.2.3. By Route of Administration
- 6.3.4.2.4. By Distribution Channel
- 6.3.5. South Korea Fabry Disease Treatment Market Outlook
- 6.3.5.1. Market Size & Forecast
- 6.3.5.2. Market Share & Forecast
- 6.3.5.2.1. By Drugs
- 6.3.5.2.2. By Treatment
- 6.3.5.2.3. By Route of Administration
- 6.3.5.2.4. By Distribution Channel
7. Europe Fabry Disease Treatment Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Drugs
- 7.2.2. By Treatment
- 7.2.3. By Route of Administration
- 7.2.4. By Distribution Channel
- 7.2.5. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Fabry Disease Treatment Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Drugs
- 7.3.1.2.2. By Treatment
- 7.3.1.2.3. By Route of Administration
- 7.3.1.2.4. By Distribution Channel
- 7.3.2. Germany Fabry Disease Treatment Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Drugs
- 7.3.2.2.2. By Treatment
- 7.3.2.2.3. By Route of Administration
- 7.3.2.2.4. By Distribution Channel
- 7.3.3. Spain Fabry Disease Treatment Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Drugs
- 7.3.3.2.2. By Treatment
- 7.3.3.2.3. By Route of Administration
- 7.3.3.2.4. By Distribution Channel
- 7.3.4. Italy Fabry Disease Treatment Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Drugs
- 7.3.4.2.2. By Treatment
- 7.3.4.2.3. By Route of Administration
- 7.3.4.2.4. By Distribution Channel
- 7.3.5. United Kingdom Fabry Disease Treatment Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Drugs
- 7.3.5.2.2. By Treatment
- 7.3.5.2.3. By Route of Administration
- 7.3.5.2.4. By Distribution Channel
8. North America Fabry Disease Treatment Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Drugs
- 8.2.2. By Treatment
- 8.2.3. By Route of Administration
- 8.2.4. By Distribution Channel
- 8.2.5. By Country
- 8.3. North America: Country Analysis
- 8.3.1. United States Fabry Disease Treatment Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Drugs
- 8.3.1.2.2. By Treatment
- 8.3.1.2.3. By Route of Administration
- 8.3.1.2.4. By Distribution Channel
- 8.3.2. Mexico Fabry Disease Treatment Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Drugs
- 8.3.2.2.2. By Treatment
- 8.3.2.2.3. By Route of Administration
- 8.3.2.2.4. By Distribution Channel
- 8.3.3. Canada Fabry Disease Treatment Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Drugs
- 8.3.3.2.2. By Treatment
- 8.3.3.2.3. By Route of Administration
- 8.3.3.2.4. By Distribution Channel
9. South America Fabry Disease Treatment Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Drugs
- 9.2.2. By Treatment
- 9.2.3. By Route of Administration
- 9.2.4. By Distribution Channel
- 9.2.5. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Fabry Disease Treatment Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Drugs
- 9.3.1.2.2. By Treatment
- 9.3.1.2.3. By Route of Administration
- 9.3.1.2.4. By Distribution Channel
- 9.3.2. Argentina Fabry Disease Treatment Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Drugs
- 9.3.2.2.2. By Treatment
- 9.3.2.2.3. By Route of Administration
- 9.3.2.2.4. By Distribution Channel
- 9.3.3. Colombia Fabry Disease Treatment Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Drugs
- 9.3.3.2.2. By Treatment
- 9.3.3.2.3. By Route of Administration
- 9.3.3.2.4. By Distribution Channel
10. Middle East and Africa Fabry Disease Treatment Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Drugs
- 10.2.2. By Treatment
- 10.2.3. By Route of Administration
- 10.2.4. By Distribution Channel
- 10.2.5. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Fabry Disease Treatment Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Drugs
- 10.3.1.2.2. By Treatment
- 10.3.1.2.3. By Route of Administration
- 10.3.1.2.4. By Distribution Channel
- 10.3.2. Saudi Arabia Fabry Disease Treatment Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Drugs
- 10.3.2.2.2. By Treatment
- 10.3.2.2.3. By Route of Administration
- 10.3.2.2.4. By Distribution Channel
- 10.3.3. UAE Fabry Disease Treatment Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Drugs
- 10.3.3.2.2. By Treatment
- 10.3.3.2.3. By Route of Administration
- 10.3.3.2.4. By Distribution Channel
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Fabry Disease Treatment Market: SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
- 16.1. Sanofi (Genzyme Corporation)
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (In case of listed companies)
- 16.1.5. Recent Developments
- 16.1.6. SWOT Analysis
- 16.2. Takeda Pharmaceutical Company Limited
- 16.2.1. Business Overview
- 16.2.2. Company Snapshot
- 16.2.3. Products & Services
- 16.2.4. Financials (In case of listed companies)
- 16.2.5. Recent Developments
- 16.2.6. SWOT Analysis
- 16.3. Amicus Therapeutics, Inc
- 16.3.1. Business Overview
- 16.3.2. Company Snapshot
- 16.3.3. Products & Services
- 16.3.4. Financials (In case of listed companies)
- 16.3.5. Recent Developments
- 16.3.6. SWOT Analysis
- 16.4. JCR Pharmaceuticals Co., Ltd.
- 16.4.1. Business Overview
- 16.4.2. Company Snapshot
- 16.4.3. Products & Services
- 16.4.4. Financials (In case of listed companies)
- 16.4.5. Recent Developments
- 16.4.6. SWOT Analysis
- 16.5. Protalix BioTherapeutics Inc.
- 16.5.1. Business Overview
- 16.5.2. Company Snapshot
- 16.5.3. Products & Services
- 16.5.4. Financials (In case of listed companies)
- 16.5.5. Recent Developments
- 16.5.6. SWOT Analysis
- 16.6. Chiesi Farmaceutici S.p.A.
- 16.6.1. Business Overview
- 16.6.2. Company Snapshot
- 16.6.3. Products & Services
- 16.6.4. Financials (In case of listed companies)
- 16.6.5. Recent Developments
- 16.6.6. SWOT Analysis
- 16.7. Freeline Therapeutics Holdings PLC
- 16.7.1. Business Overview
- 16.7.2. Company Snapshot
- 16.7.3. Products & Services
- 16.7.4. Financials (In case of listed companies)
- 16.7.5. Recent Developments
- 16.7.6. SWOT Analysis
- 16.8. Yuhan Corporation
- 16.8.1. Business Overview
- 16.8.2. Company Snapshot
- 16.8.3. Products & Services
- 16.8.4. Financials (In case of listed companies)
- 16.8.5. Recent Developments
- 16.8.6. SWOT Analysis
- 16.9. M6P Therapeutics
- 16.9.1. Business Overview
- 16.9.2. Company Snapshot
- 16.9.3. Products & Services
- 16.9.4. Financials (In case of listed companies)
- 16.9.5. Recent Developments
- 16.9.6. SWOT Analysis
- 16.10.ISU Abxis Co Ltd
- 16.10.1. Business Overview
- 16.10.2. Company Snapshot
- 16.10.3. Products & Services
- 16.10.4. Financials (In case of listed companies)
- 16.10.5. Recent Developments
- 16.10.6. SWOT Analysis
17. Strategic Recommendations
18. About Us & Disclaimer
